 HOUSTON, Sept. 01, 2022 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. Nasdaq: BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference hybrid. A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website. 